Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of BioMed rTSST-1 Variant Vaccine in Healthy Adults
2015-003714-24Phase 2Completed
- Sponsor
- Biomedizinische Forschungs- und Bio-Produkte
- Start
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rTSST-1 variant vaccine in staphylococcal toxic shock syndrome (TSS), sponsored by Biomedizinische Forschungs- und Bio-Produkte. Primary endpoint: adverse events. Started Oct 2015; status: completed.
02
Drugs
rTSST-1 variant vaccine
03
Conditions
staphylococcal toxic shock syndrome (TSS)
Beyond the preview
Go deeper on 2015-003714-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003714-24.